文献速递糖尿病

中国慢性肾脏病合并2型糖尿病患者启动非奈利酮治疗的临床特征、有效性与安全性结局:来自FOUNTAIN平台的回顾性真实世界队列研究

Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-09

该回顾性研究利用中国天津电子健康记录,纳入2023年1月至2024年12月启动非奈利酮的成人慢性肾脏病合并2型糖尿病患者6537例。第4个月时中位UACR下降40.7%(95%CI:32.2%,49.1%),平均eGFR下降3.2%(95%CI:2.4%,4.0%),平均血清钾升高4.6%(95%CI:3.9%,5.3%),高钾血症事件发生率为4.1/100人年。作者认为这些发现强化了非奈利酮在中国真实世界临床实践中的有效性和安全性。

要点

  • 共纳入6537例启动非奈利酮的中国CKD合并T2D患者,66.4%为男性,平均年龄57.6岁。
  • 第4个月中位UACR下降40.7%,平均eGFR下降3.2%,平均血清钾升高4.6%。
  • 高钾血症事件发生率为4.1/100人年,随访期间总体耐受良好。

核心结论

  • 启动非奈利酮的CKD合并T2D患者UACR大幅下降、eGFR轻度下降,随访期间总体耐受良好。
  • 作者认为这些发现强化了非奈利酮在中国真实世界临床实践中的有效性和安全性。

研究设计与样本

  • 回顾性研究,使用中国天津的电子健康记录。
  • 纳入2023年1月至2024年12月启动非奈利酮的成人CKD合并T2D患者,共6537例(66.4%为男性,平均年龄57.6岁)。

主要发现

  • 97.0%有基线UACR和eGFR值的患者属于KDIGO中危、高危或极高危风险类别。
  • 第4个月中位UACR下降40.7%(95%CI:32.2%,49.1%),平均eGFR下降3.2%(95%CI:2.4%,4.0%),平均血清钾升高4.6%(95%CI:3.9%,5.3%)。
  • 上述趋势在各亚组间总体一致。
  • 高钾血症事件发生率为4.1/100人年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims Finerenone was approved in China in 2022 for adult patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D). This study aimed to characterize Chinese patients with CKD and T2D who initiated finerenone in routine clinical practice and to evaluate treatment outcomes. Materials and Methods This retrospective study used electronic health records from Tianjin, China, and included adult patients with CKD and T2D who initiated finerenone between January 2023 and December 2024. Baseline characteristics were summarized. Relative changes in urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR) and serum potassium were assessed. Recorded hyperkalaemia events were evaluated during follow-up. Key outcomes were examined in the overall cohort and across subgroups. Results A total of 6537 patients were included (66.4% male; mean age 57.6 years). Of these, 97.0% with baseline UACR and eGFR values were categorized as moderate, high, or very high Kidney Disease: Improving Global Outcomes (KDIGO) risk categories. At Month 4, median UACR decreased substantially by 40.7% (95% confidence interval [CI]: 32.2%, 49.1%), the mean eGFR declined slightly by 3.2% (95% CI: 2.4%, 4.0%) and the mean serum potassium increased by 4.6% (95% CI: 3.9%, 5.3%). These trends were generally consistent across subgroups. The incidence rate of hyperkalaemia events was 4.1 per 100 person-years. Conclusions Patients with CKD and T2D who initiated finerenone experienced a substantial reduction in UACR, a slight decrease in eGFR, and were generally well tolerated during follow-up. These findings reinforce the effectiveness and safety of finerenone in Chinese real-world clinical practice.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。